1 1 2 3 A cross-brain-regions study of ANK1 DNA methylation in 4 different neurodegenerative diseases. 5 6 7 8 ABSTRACT 1 2 Recent epigenome-wide association studies in Alzheimer's disease have highlighted 3 consistent robust neuropathology-associated DNA hypermethylation of the Ankyrin 1 4 (ANK1) gene in the cortex. The extent to which altered ANK1 DNA methylation is 5 also associated with other neurodegenerative diseases is not currently known. In the 6 current study, we used bisulfite pyrosequencing to quantify DNA methylation across 7 eight CpG sites within a 118bp region of the ANK1 gene across multiple brain 8 regions in Alzheimer's disease, Vascular dementia, Dementia with Lewy bodies,
INTRODUCTION

2
Dementia encompasses a group of chronic neurodegenerative diseases that affected 3 an estimated 46.8 million people worldwide in 2015 (Wimo et al., 2017) , of which 4 Alzheimer's disease (AD) accounts for ~60% of cases. The etiology of AD has been 5 hypothesized to involve epigenetic mechanisms (Lunnon and Mill, 2013) . In 2014 two 6 epigenome-wide association studies (EWAS) of AD identified significant 7 hypermethylation of CpG sites in the Ankyrin 1 (ANK1) gene associated with 8 neuropathology in AD cortex (De Jager et al., 2014; Lunnon et al., 2014) , which has 9 been replicated in multiple independent study cohorts (Smith, 2017) . Subsequently, a 10 genome wide association study (GWAS) of a Han Chinese population identified a 11 single-nucleotide polymorphism (SNP) in ANK1 associated with an increased 12 susceptibility for developing AD (Chi et al., 2015) . ANK1 links integral membrane 13 proteins to the underlying spectrin-actin cytoskeleton and plays a key role in cell 14 motility, activation, proliferation, contact, and maintenance of specialized membrane 15 domains (Yang et al., 2011) . There is now increasing interest in understanding the 16 role of epigenetic changes in ANK1 in the development and progression of AD. One 17 important question to be addressed is whether ANK1 hypermethylation is specific to 18 AD, or observed in other neurodegenerative disorders. Although AD accounts for 19 ~60% of dementia cases, many other dementias share common symptoms and/or 20 pathological hallmarks with AD.
22
This study aimed to quantify DNA methylation levels across a 118bp region of ANK1, 23 previously associated with AD, in a number of different neurodegenerative diseases.
24
Using bisulfite pyrosequencing we assessed ANK1 DNA methylation in brain Post-mortem brain tissue was obtained from six different UK brain banks (the South 8 West Dementia Brain Bank (SWDBB), the London Neurodegenerative Disease Brain 9 Bank (LNDBB) the Manchester Brain Bank, the Oxford Brain Bank, the Cambridge 10 Brain Bank and the Newcastle Brain Bank). In total, tissue was obtained from 60 AD 11 119 DLB, 27 VaD, 22 HD, 36 PD and 105 elderly non-demented control 12 subjects (Braak 0-II). A subset of DLB (N = 39) and VaD (N = 5) cases also had co-13 existing AD pathology. For each disease we analyzed the entorhinal cortex (EC),
14
superior temporal gyrus (STG) and cerebellum (CER). For HD cases we also 15 analyzed the striatum (STR) as this is primarily affected in disease (Reiner et al., 16 2011), whilst for PD cases we analyzed the STR and substantia nigra (SN) as these 17 are regions of pathology in this disease (Fearnley and Lees, 1991) . For control 18 samples we analyzed all five brain regions. For a small number of donors tissue was 19 not available from all brain regions. Genomic DNA was isolated from ~100mg of each 20 dissected brain region using a standard phenol-chloroform extraction method, and 21 tested for degradation and purity prior to analysis as previously described (Smith et 22 al., 2016) . Demographic information for samples can be found in Supplementary 23 individual CpG sites in the ANK1 gene, spanning from 41519302 to 41519420 within 28 chromosome 8 (hg19). Bisulfite conversion was performed using the Bisulfite-Gold kit 1 (Zymo research, USA). A single amplicon (246bp) was generated using primers 2 designed using the PyroMark Assay Design software 2.0 (Qiagen, UK) as previously 3 described (Lunnon et al., 2014) . Pyrosequencing was performed using two 4 sequencing primers to maximize coverage across eight CpG sites. DNA methylation 5 was quantified using the Pyromark Q24 system (Qiagen, UK) following the 6 manufacturer's standard instructions and the Pyro Q24 CpG 2.0.6 software. 
24
AD-associated ANK1 DNA hypermethylation is seen across all tissues
25 analyzed 26 First, we sought to replicate previous findings of ANK1 DNA hypermethylation in AD.
27
Across the 118bp region, we observed significantly increased levels in AD cases 28 compared to controls in all eight ANK1 CpG sites in the EC (Figure 1A) and seven 1 ANK1 CpG sites in the STG (Figure 1B) . Both the EC and STG exhibit a high degree 2 of AD pathology, even in the earliest stages of disease, with the EC being the starting 3 point of AD pathology in the cortex with pathology seen here in Braak stage II (Braak 4 and Braak, 1991) . Conversely, the CER remains free of AD pathology until the very 5 last stages of the disease, although even then this is limited to amyloid beta (Aβ) 6 plaques with an absence of neurofibrillary tangles (NFTs) of hyperphosphorylated tau 7 (Braak et al., 1989) . Of note, we observed significant ANK1 DNA hypermethylation at 8 five ANK1 CpG sites in the CER (Figure 1C) . This is the first time ANK1 DNA 9 methylation changes have been reported in the CER. Interestingly, two of the loci 10 that did not display AD-associated ANK1 hypermethylation in the CER were 11 chr8:41519308 and chr8:41519399, the two sites included on the Illumina 450K array 12 used in previous EWAS analyses of AD which did not identify ANK1 13 hypermethylation in AD in the CER (Lunnon et al., 2014) . Average DNA methylation 
22
Interestingly, this pattern of change matches the spread of AD pathology throughout 23 the brain.
25
ANK1 DNA hypermethylation in the EC is only observed in DLB cases
26 with co-existing AD pathology 27 1 50 to 83 years (McKeith, 2002) . The pathology of DLB shares similarities to AD, with 2 the presence of immune regulation and microglial activation being consistent 3 between diseases (Mackenzie, 2000) . However, the presence of Lewy bodies within 4 the brain makes DLB considerably more comparable to PD (McKeith, 2002) . In fact,
5
PD dementia is thought to be biologically identical to DLB, only differing in the order 6 in which the motor or cognitive symptoms occur (Dodel et al., 2008) . Interestingly we 7 observed significant hypermethylation of ANK1 in DLB cases compared to controls in 8 the EC (Figure 2A) at four of the eight ANK1 CpG sites ( Supplementary Table 3 ).
9
We saw no difference between DLB and control samples in either the STG 10 ( Supplementary Figure 1A) or the CER (Supplementary Figure 1B) at any of the 11 eight ANK1 CpG sites. Across the ANK1 amplicon we observed significant DLB-12 associated hypermethylation in the EC (P = 0.0244), but not in the STG or CER (P > 13 0.05) (Figure 2B) . It is widely reported that DLB and AD frequently co-occur 14 (Rosenberg et al., 2001) ; we were therefore interested to investigate whether we still 15 observed DLB-associated DNA hypermethylation in the EC when we controlled for 16 co-existing AD pathology. We found no significant changes in ANK1 DNA 17 methylation in individuals with "pure" DLB compared to controls in the EC (Figure   18 2C), STG (Supplementary Figure 1C) and CER (Supplementary Figure 1D ).
19
However, we did observe significant hypermethylation in DLB cases with co-existing 20 AD pathology compared to controls at seven of the eight ANK1 CpG sites in the EC 21 ( Figure 2C ) and two sites in the STG (Supplementary Figure 1C) , with no 22 difference in the CER (Supplementary Figure 1D) . When we looked across the 23 whole 118bp region, we saw increased ANK1 DNA methylation in the EC in 24 individuals with co-existing AD pathology (P = 1.45 x 10 -03 ) ( Figure 2D ), suggesting 25 that the ANK1 hypermethylation seen in some individuals with DLB is primarily driven 26 by AD pathology.
28
ANK1 hypermethylation is seen in the EC only in VaD individuals with
1 co-existing AD pathology 2 Characterized by the loss of neurological function due to ischemic events, the risk of 3 developing VaD is closely linked to vascular health (Román et al., 1993) . We 4 observed increased DNA methylation in individuals with VaD at none of the ANK1 5 CpG sites in the EC (Figure 3A) , only one site in the STG (Supplementary Figure   6 2A) and no sites in the CER (Supplementary Figure 2B) (Supplementary Table 4) , 7 with no difference across the amplicon in any of the brain regions tested (P > 0.05) 8 ( Figure 3B) . Because VaD also often co-occurs with AD we next examined whether 9 stratifying cases by the presence of AD pathology altered these findings.
10
Interestingly, we saw disease-associated hypermethylation in the EC at five of the 11 eight ANK1 CpG sites only in individuals with co-existing AD pathology (Figure 3C (Supplementary Figure 2D) . When we looked 15 across the 118bp region we only saw significant ANK1 hypermethylation in 16 individuals with VaD and co-existing AD pathology compared to controls in the EC (P 17 = 0.0163) ( Figure 3D) . It is worth noting that our cohort only had a small number of 18 VaD cases with co-existing AD pathology (N=5).
20
ANK1 DNA hypermethylation in the EC is seen in both HD and PD.
21
HD is characterized by a trinucleotide repeat in the huntingtin gene (HTT). The
22
abundance of the repeat is proportional to the level of protein misfolding and 23 downstream cytosolic accumulation, leading to neuronal cell death and the 24 symptoms of HD (Walker, 2007) . ANK1 DNA hypermethylation was seen at four of 25 the eight CpG sites in the EC in HD (Figure 4A) . However, no differential DNA 26 methylation was seen in the other brain regions tested ( Supplementary Table 5 ),
27
including the STG (Supplementary Figure 3A) , the CER (Supplementary Figure  3B ) and the STR (Supplementary Figure 3C) , a region that forms part of the basal 1 ganglia, known to be the first brain region to be adversely affected by HD pathology 2 (Walker, 2007) . Averaging across the region again highlighted significant 3 hypermethylation in the EC (P = 6.68 x 10 -3 ), with no significant change in any other 4 tissue ( Figure 4B ).
6
A similar pattern of ANK1 hypermethylation was observed in PD; two of the eight 7 CpG sites were characterized by significant hypermethylation in the EC (Figure 4C) , 8 with no differences in DNA methylation in any of the other brain regions tested 9 ( Supplementary Table 6 ). This included the STG (Supplementary Figure 4A) , the 10 CER (Supplementary Figure 4B) , the STR (Supplementary Figure 4C ) and the SN 11 (Supplementary Figure 4D) , with the SN representing the brain region that has the 12 highest levels of pathology in PD (Fearnley and Lees, 1991) . Across the 118bp 13 amplicon we saw no change in DNA methylation in any of the five brain regions 14 (Figure 4D) . 
19
This is the first study to assess brain ANK1 DNA methylation changes across 20 multiple neurodegenerative diseases. We identified significant DNA methylation 21 changes in the EC in multiple diseases, including AD, HD and PD, with significant 22 DNA hypermethylation across the amplicon in AD and HD. Interestingly, we also 23 observed significant hypermethylation of ANK1 in the EC in both DLB and VaD at 24 several individual CpG sites and across the amplicon, but only in donors with co-25 existing AD pathology. This suggests that ANK1 DNA hypermethylation in the EC is 26 specific to some neurodegenerative diseases (AD, HD and to some extent PD), and 27 not observed in other forms of neuropathology (VaD and DLB). Although it is possible 28 that the observed changes in ANK1 could reflect a common feature of 1 neurodegenerative diseases, such as neuroinflammation, it is worth noting that we 2 did not observe ANK1 DNA hypermethylation in all diseases, for example we did not 3 see any hypermethylation in individuals with "pure" DLB or VaD. These diseases are 4 also characterised by neuroinflammation, so this suggests that the observed 5 hypermethylation does not simply reflect a common hallmark of all 6 neurodegenerative diseases such as microgliosis. We have previously reported that 7 ANK1 is not hypermethylated in the CER in AD at two sites interrogated by the 8 Illumina 450K array (chr8:41519308 and chr8:41519399). In the current study we 9 again demonstrate that these two loci are not significantly differentially methylated in 10 AD; however, we do highlight AD-associated DNA hypermethylation at five adjacent
11
CpG sites and averaged across the 118bp amplicon in the CER. We did not see any
12
ANK1 DNA methylation changes in the CER in any of the other neurodegenerative 13 diseases, including those with co-existing AD pathology. Reflecting our previous 14 findings, we found that DNA methylation differences in AD are greatest in the EC, an 15 area with high levels of neuropathology and lowest in the CER, the region with the 16 least neuropathology. Interestingly, although we observed disease-associated ANK1 17 hypermethylation in the EC at six individual sites and across the region in HD and at 18 two individual sites in PD, we did not see ANK1 DNA methylation changes in these interpretation of the DNA methylation differences we observe. Mastroeni et al., 1 recently showed a four-fold increase in ANK1 mRNA expression in microglia from AD 2 brain tissue, but not in neurons or astrocytes from the same individuals, suggesting 3 an immune based function for ANK1 in the human brain (Mastroeni et al., 2017) . One 4 potential caveat of our study is that we have analyzed "bulk" tissue, and we cannot 5 determine which cell type(s) are driving the DNA hypermethylation seen in ANK1 in 6 disease.
8
Although the focus of our study was on investigating DNA methylation changes in 9 disease, bisulfite pyrosequencing actually generates a summative measurement of 10 both DNA methylation and DNA hydroxymethylation. DNA methylation is generally 11 associated with gene silencing, particularly when residing in the promoters of 12 constitutively expressed housekeeping genes (Jones, 2012) , whilst DNA 13 hydroxymethylation has been shown to be enriched in gene bodies (Lunnon et al., 14 2016 ) and to be found at (relatively) high levels in the brain (Khare et al., 2012;  15 Szulwach et al., 2011) . We have recently shown that ANK1 DNA hypermethylation 16 across the 118bp amplicon in AD is actually underestimated when using bisulfite 17 data, as it is confounded by significant DNA hypohydroxymethylation at some loci in 18 the amplicon (Smith et al., Under Review) . Another caveat to our study is that we 
25
Our study has demonstrated disease-associated ANK1 hypermethylation in the EC at 26 specific CpG sites in AD, HD and PD and across the region in AD and HD. In donors 27 with DLB and VaD we only observed increased ANK1 DNA methylation in the EC in 28 individuals with co-existing AD pathology. The CER showed disease-associated 1 hypermethylation at specific CpG loci and across the region in AD, but not in any of 2 the other neurodegenerative diseases tested. We saw no disease-associated 3 differential ANK1 DNA methylation in the STR in HD or PD, or the SN in PD. This 4 suggests that ANK1 is characterized by brain region and disease-specific differential 5 DNA methylation in different neurodegenerative diseases. It is unlikely that the 6 identified DNA methylation changes in ANK1 could be useful as a biomarker 7 clinically, as we have previously shown that ANK1 is not hypermethylated in blood in 8 AD (Lunnon et al., 2014) . However, these epigenetic changes could represent novel 9 therapeutic targets for disease, if shown to be causal in pathology. At present we are 10 unable to determine whether these changes represent a cause or a consequence of 11 the disease process. Further functional studies should therefore be performed to 12 determine the potential disease causality of this modification. 
